Duopharma Biotech Berhad Company Description
Duopharma Biotech Berhad, an investment holding company, researches, develops, manufactures, distributes, and imports pharmaceutical products and medicines in Malaysia and internationally.
The company offers consumer healthcare products comprising vitamins and supplements, analgesics, eyecare, antacids, and skin care products; and generic drugs for various therapeutic classes, such as cardiovascular, dermatology, hormones, respiratory, sensory and nervous system, musculo-skeletal system, anti-infectives, and others.
It also provides specialty pharmaceutical drugs for targeted conditions, biosimilar products, and medical devices and consumables to patients with conditions, such as diabetes, cancer, cardiovascular diseases, renal diseases, and others.
The company’s product portfolio comprises vascor, acetan, covasc, crystorvas, bezartan, vytan, and vytocor; insugen and basalog one; kytron, zuhera, lebreta, trevive, and krabeva; and unihepa, ranofer, erysaa, bi-haemosol, and haemosol.
The company offers its products under the Champs, Flavettes, Eye Glo, Proviton, Naturalle, and Uphamol brands.
In addition, it offers property management and services; and distributes, imports, and exports chemical products.
The company was formerly known as CCM Duopharma Biotech Berhad and changed its name to Duopharma Biotech Berhad in February 2019.
Duopharma Biotech Berhad was founded in 1978 and is headquartered in Kuala Lumpur, Malaysia.
Country | Malaysia |
Founded | 1978 |
Industry | Pharmaceutical Preparations |
Employees | 1,650 |
CEO | Ariff bin Abdul Shatar |
Contact Details
Address: CIMB HUB Kuala Lumpur, 50250 Malaysia | |
Phone | 60 3 2162 0218 |
Website | duopharmabiotech.com |
Stock Details
Ticker Symbol | DPHARMA |
Exchange | Bursa Malaysia |
Fiscal Year | January - December |
Reporting Currency | MYR |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Ariff bin Abdul Shatar | Chief Executive Officer |
Wu Chek | Chief Financial Officer |